-+ 0.00%
-+ 0.00%
-+ 0.00%
Turning Point Brands (TPB) Lifts 2026 Guidance, Is The Stock Already Pricey?
Share
Listen to the news

Turning Point Brands (TPB) has drawn fresh attention after raising its 2026 earnings guidance tied to Modern Oral products. The update comes alongside recent sales figures and the launch of FRE Labs flavor drops.

See our latest analysis for Turning Point Brands.

Despite the stronger Modern Oral outlook and the launch of FRE Labs, Turning Point Brands' share price has softened recently, with the stock down 22.62% year to date on a share price basis, while still showing a very large 3 year total shareholder return of 257% and a 5 year total shareholder return of 82.23%.

If you are assessing how product stories can reshape future return potential, this is a good moment to broaden your search and check out 21 top founder-led companies

Turning Point Brands now trades at a steep discount to both analyst targets and one intrinsic value estimate, even after the guidance lift and FRE Labs launch. Is the market being prudent about the risks, or too cautious about the upside potential?

Most Popular Narrative: 34.4% Undervalued

At a last close of $85.30 versus a fair value narrative of $130, Turning Point Brands is framed as meaningfully discounted, with that gap pinned on Modern Oral momentum and margin assumptions.

Strong growth in the Modern Oral nicotine pouch segment, with sales growing nearly 8x year-over-year and now accounting for 26% of total revenue, positions TPB to capture significant market share in a category projected to reach $10 billion by decade's end. This is expected to support long-term revenue and margin expansion as the modern oral segment scales and premiumizes.

Read the complete narrative.

Want to see the math behind that $130 tag for Turning Point Brands? The key hinges on fast compounding revenue, rising margins, and a rich future earnings multiple that leans well above sector norms.

Result: Fair Value of $130 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Turning Point Brands still faces meaningful risks if Modern Oral growth slows or regulators tighten rules around nicotine pouches, which could undermine the bullish valuation story.

Find out about the key risks to this Turning Point Brands narrative.

Another View on Turning Point Brands

The analyst narrative presents Turning Point Brands as undervalued at a $130 fair value. However, the current P/E of 38.4x suggests a different perspective. It is higher than the estimated fair ratio of 33.1x, the global Tobacco average of 12x, and a peer average of 35.1x. Is the market already paying up for the Modern Oral story?

For a closer look at what this gap in ratios could mean for your risk and return trade off, See what the numbers say about this price — find out in our valuation breakdown.

NYSE:TPB P/E Ratio as at Aug 2026
NYSE:TPB P/E Ratio as at Aug 2026

Next Steps

If this Turning Point Brands story feels finely balanced between optimism and caution, act now by reviewing both sides of the equation through 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Turning Point Brands?

If the Turning Point Brands setup has sharpened your focus, now is the time to scan wider and spot other opportunities before they move without you.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending